Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beta-blockade with landiolol in out-of-hospital cardiac arrest
2024-518949-14-00Phase 2Authorised
- Sponsor
- Medical University of Vienna
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cardiac arrest (SCA), ventricular fibrillation (VF) and pulseless ventricular tachycardia comparing Landiolol (Rapibloc) with Placebo (0.9% sodium chloride) (2 arms). Primary endpoint: Time to sustained return of spontaneous circulation. Planned start Dec 2024; status: authorised.
02
Drugs
landiolol
03
Conditions
cardiac arrest (SCA)ventricular fibrillation (VF)pulseless ventricular tachycardia
Beyond the preview
Go deeper on 2024-518949-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518949-14-00.